FDA Panel Deems Non-inferiority Trials For J&J’s Doribax Inferior
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anti-Infective Drugs Advisory votes 10-3 that a 20 percent non-inferiority margin for the antibiotic is not scientifically justifiable.
You may also be interested in...
J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.
J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.
FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date
Firm says FDA and company audits of telavancin clinical trial data are progressing well; no predictions on how long process may take.